This upregulation activates NK cell cytotoxicity through the NKG2D/MICA signaling axis.[20] Thus, activating the tumor‐killing function of NK cells through the NKG2D/MICA signaling axis is considered a promising approach to enhancing drug treatment efficacy. This evidence concerns the gene KLRK1 and neoplasm.